Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 27,757 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo and sham treatment Clear all
Completed Not applicable Interventional

Thiamine, Vitamin C and Hydrocortisone in the Treatment of Septic Shock

NCT03540628
View directory record Official record
Conditions
Septic Shock
Interventions
Thiamine and Vitamin C
Dietary Supplement
Lead sponsor
Corewell Health South
Other
Eligibility
18 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Saint Joseph, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 16, 2026, 4:00 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease

NCT03891667
View directory record Official record
Conditions
Fatigue, Quality of Life
Interventions
Disulfiram
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 16, 2026, 4:00 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Angiotensin-(1-7) Cardiovascular Effects in Aging

NCT05301192
View directory record Official record
Conditions
Aging
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
65 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 16, 2026, 4:00 AM EDT
Completed Phase 2 Interventional

Effects of Quercetin on Blood Sugar and Blood Vessel Function in Type 2 Diabetes.

NCT01839344
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Quercetin, Acarbose, placebo
Dietary Supplement · Drug
Lead sponsor
Bastyr University
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 16, 2026, 4:00 AM EDT
Active, not recruiting Phase 2 Interventional

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

NCT07446998
View directory record Official record
Conditions
Obesity & Overweight, Mobility Disability, HOMA-IR
Interventions
Enobosarm, Semaglutide (Wegovy) weekly injection
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
65 Years to 100 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Doral, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 16, 2026, 4:00 AM EDT
Completed Phase 2 Interventional Results available

Naltrexone and Memantine Effects on Alcohol Drinking Behaviors

NCT01519063
View directory record Official record
Conditions
Alcohol Drinking
Interventions
Naltrexone and memantine first, Naltrexone and Placebo first
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 16, 2026, 4:00 AM EDT
Completed Phase 4 Interventional Results available

Screening to Prophylax Against Clostridium Difficile Infection -

NCT02996487
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Vancomycin, Placebo
Drug · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
1,294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Dearborn, Michigan • Royal Oak, Michigan • Troy, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 16, 2026, 4:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear Healthy Controls.

NCT01733030
View directory record Official record
Conditions
Post Traumatic Stress Syndrome
Interventions
Seromycin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 16, 2026, 4:00 AM EDT
Terminated Phase 3 Interventional

Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression

NCT03942419
View directory record Official record
Conditions
Myopia
Interventions
Atropine 0.1% Ophthalmic Solution, Atropine 0.01% Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
3 Years to 12 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
Birmingham, Alabama • Glendale, Arizona • Azusa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Oct 16, 2026, 4:00 AM EDT
Terminated Phase 1 Interventional

Single Ascending Dose Trial in Patients With Type 2 Diabetes

NCT01492465
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
AMG 876
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Omaha, Nebraska • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 16, 2026, 4:00 AM EDT
Active, not recruiting Not applicable Interventional

Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease

NCT03865992
View directory record Official record
Conditions
Breast Cancer, Joint Pain
Interventions
Curcumin, Placebo, Nanoemulsion, Quality-of-Life Assessment, Questionnaire
Dietary Supplement · Other · Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
4
States / cities
Duarte, California • Rancho Cucamonga, California • South Pasadena, California + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 16, 2026, 4:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Painful Osteoarthritis of the Knee

NCT00379236
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
EUFLEXXA™, placebo
Device
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
588 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2011 · Synced Oct 16, 2026, 4:00 AM EDT
Completed Early Phase 1 Interventional

Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis

NCT03114111
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
aminolevulinic acid (ALA), Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 16, 2026, 4:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Muscle Mass During Space Exploration

NCT00968344
View directory record Official record
Conditions
Muscle Loss
Interventions
Leucine, Alanine
Dietary Supplement
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
45 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 16, 2026, 4:00 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity

NCT00364871
View directory record Official record
Conditions
Obesity
Interventions
naltrexone and bupropion SR
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
7
States / cities
San Diego, California • Augusta, Georgia • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 16, 2026, 4:00 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM

NCT05405244
View directory record Official record
Conditions
Overweight and Obesity, Eating Behavior
Interventions
Placebo, Bromocriptine-QR
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 16, 2026, 4:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety of the Coadministration of ANS-6637 and Ethanol

NCT03203499
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ANS-6637 Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Amygdala Neurosciences, Inc.
Industry
Eligibility
21 Years to 45 Years · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 16, 2026, 4:00 AM EDT
Terminated Not applicable Interventional Results available

Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients (GCC1232)

NCT01881932
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer
Interventions
Acupuncture using Seirin® needles, Sham Acupuncture using Park Sham placebo acupuncture device
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 16, 2026, 4:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Expectations on Negative Affect, Perceived Cognitive Effort, and Pain

NCT05425563
View directory record Official record
Conditions
Placebo, Expectations
Interventions
Pain Expectancy Cues, Vicarious Pain Expectancy Cues, Cognitive Effort Expectancy Cues
Behavioral
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years to 55 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 16, 2026, 4:00 AM EDT
Completed Phase 3 Interventional Results available

A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03435081
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
60
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 16, 2026, 4:00 AM EDT
Completed Phase 2Phase 3 Interventional

A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

NCT00134199
View directory record Official record
Conditions
Obesity
Interventions
CP-945,598, sibutramine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
15
States / cities
Clearwater, Florida • Kissimmee, Florida • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2009 · Synced Oct 16, 2026, 4:00 AM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy

NCT06537999
View directory record Official record
Conditions
Multifocal Motor Neuropathy
Interventions
Claseprubart, Placebo
Drug
Lead sponsor
Dianthus Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Scottsdale, Arizona • Los Angeles, California • Bradenton, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 16, 2026, 4:00 AM EDT
Terminated Phase 2 Interventional Results available

AGN-242428 in the Treatment of Plaque Psoriasis

NCT03339999
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
AGN-242428, Placebo
Drug
Lead sponsor
Vitae Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 16, 2026, 4:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Novel Supplement on Glycemic Variability Measured by Continuous Glucose Monitoring

NCT05832463
View directory record Official record
Conditions
Healthy
Interventions
Carbohydrate blocking supplement (CBS), Placebo capsule
Dietary Supplement
Lead sponsor
dōTERRA International
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pleasant Grove, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 16, 2026, 4:00 AM EDT